subscribeSubscribe
Gilteritinib as Maintenance Therapy Shows Benefit in Subgroups of FLT3-ITD

Gilteritinib as Maintenance Therapy Shows Benefit in Subgroups of FLT3-ITD
PR NEWSWIRE
09 Jun 2023
Share Share
Astellas Xospata comes up short again in bid to expand leukemia use

Astellas Xospata comes up short again in bid to expand leukemia use
Kevin Dunleavy FIERCE PHARMA
10 Mar 2023
Share Share
Astellas and BMT CTN Announce Results from PIII MORPHO Trial of Gilteritinib

Astellas and BMT CTN Announce Results from PIII MORPHO Trial of Gilteritinib
PR NEWSWIRE
09 Mar 2023
Share Share
FDA Confirms Paragraph IV Patent Litigation for Gilteritinib Fumarate Tablets

FDA Confirms Paragraph IV Patent Litigation for Gilteritinib Fumarate Tablets

FDA
13 Feb 2023
Share Share
Kronos Begins Dosing in PIb/II Trial of Lanraplenib with Gilteritinib

Kronos Begins Dosing in PIb/II Trial of Lanraplenib with Gilteritinib
GLOBENEWSWIRE
22 Aug 2022
Share Share
Gilteritinib clinical activity in r/r FLT3 mutated AML

Gilteritinib clinical activity in r/r FLT3 mutated AML
ONLINELIBRARY
12 Jan 2022
Share Share
Astellas finds the silver lining in failed trial for Xospata

Astellas finds the silver lining in failed trial for Xospata
K. Dunleavy FIERCEPHARMA
15 Dec 2021
Share Share
Astellas` XOSPATA® (gilteritinib) Meets Overall Survival Endpoint in COMMODORE

Astellas` XOSPATA® (gilteritinib) Meets Overall Survival Endpoint in COMMODORE
PRNEWSWIRE
29 Mar 2021
Share Share
Astellas` XOSPATA® (gilteritinib) Receives Conditional Approval by China`s

Astellas` XOSPATA® (gilteritinib) Receives Conditional Approval by China`s
PRNEWSWIRE
03 Feb 2021
Share Share
Astellas to Present New Data on Gilteritinib in FLT3 Mutation-+VE Acute Myeloid

Astellas to Present New Data on Gilteritinib in FLT3 Mutation-+VE Acute Myeloid
PRNEWSWIRE
16 Nov 2020
Share Share